share_log

JonesTrading Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $12

JonesTrading Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $12

Jones Trading以买入评级启动Inhibikase治疗药物的覆盖范围,宣布目标价为12美元
Benzinga Real-time News ·  2021/07/15 09:32

JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.

Jones Trading分析师Soumit Roy以买入评级启动Inhibikase治疗公司(纳斯达克市场代码:IKT)的报道,并宣布目标价为12美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发